Improving Outcomes in Diabetes: Focus on SGLT2 Inhibitors. A Medical Experts Discussion

Published: 01 April 2021

  • Views:

    Views Icon 143
  • Likes:

    Heart Icon 0

Overview

Full programme

  • Views:

    Views Icon 143
  • Likes:

    Heart Icon 0

Overview

This programme has been created with a view to educate primary care healthcare professionals in the UK to understand when, and for whom, they should prescribe SGLT2 inhibitors and to understand the latest advancements in this drug class.

 

Boehringer Ingelheim Ltd has supported this event as a Medical Education Grant and has had no other involvement in the organisation or the delivery of this programme.

Key Learning Objectives

  • Describe how and when to prescribe SGLT2 inhibitors
  • Identify patients who are suitable for SGLT2 inhibitors
  • Provide appropriate patient education and advice when initiating SGLT2 inhibitors
  • Recall the patient populations in whom SGLT2 inhibitors have proven efficacy and safety

Faculty

  • Dr Jas Gill - GP with Special Interest in Cardiology
  • Dr Andrew Frankel - Consultant Nephrologist
  • Dr Derek Connolly - Consultant Interventional Cardiologist
  • Su Down - Nurse Consultant in Diabetes

Series overview

Part 1

Welcome and Introductions

1 session

  • Jas Gill, Andrew Frankel, Derek Connolly, Su Down

    Watch now

Part 2

SGLT2 inhibitors: Initiation in Diabetic Kidney Disease

1 session

Part 3

SGLT2 Inhibitors in Heart Failure

1 session

Part 4

Practical aspects of initiating in Diabetes

1 session

Part 5

Practical Prescribing

1 session

Faculty biographies